What is the route of administration for Cidofovir in CMV treatment?

Cidofovir is primarily administered intravenously (IV) for the treatment of cytomegalovirus (CMV) infections. This is due to several factors, including the drug’s pharmacokinetics and the nature of the infections it targets.

As an antiviral medication, Cidofovir is used to treat CMV retinitis, particularly in immunocompromised patients, such as those with AIDS. The intravenous route allows for direct delivery into the bloodstream, ensuring higher systemic concentrations of the drug that are crucial for effectively combating viral infections. IV administration also helps manage potential side effects and dosing more efficiently, as the drug can be closely monitored and adjusted as needed during therapy.

Other routes like oral ingestion or topical application would not achieve adequate levels in the bloodstream to effectively treat systemic viral infections such as CMV. Inhalation is not relevant here as it pertains to respiratory routes, which are inappropriate for a drug intended to treat systemic viral infections. The intravenous route, therefore, optimally addresses both the pharmacokinetic requirements of Cidofovir and the clinical needs of patients with CMV infections.